Top Workforce Trends in the Global Life Sciences Industry in 2021

Apr 28, 2021 | Global

It has been quite a year for the entire world, but it has been a defining year for life sciences companies. Under incredible pressure and a global microscope, the industry has come out more resilient and stronger than ever, thanks in large part to incredible talent.

We see six trends that show how the immense growth ties to the right global workforce.

Scientific breakthroughs continue to rise, R&D dollars surge

The world’s biggest life sciences companies worked together this year like never before. In a unified race to find an effective Covid-19 vaccine, information sharing across usual boundaries was required to meet the public’s most pressing health crisis. Even before the pandemic took hold, research and development spend was up 22%. Then came greater demand for innovation and partnerships amid the pandemic.   

Increased investor risk and confidence

Scientific breakthroughs have sustained investor enthusiasm for global life science companies. Global biopharma IPOs have raised more than $20 billion — each year bringing in more than in any previous year during the last decade, according to BioWorld data. In the first three quarters of 2019, early- and angel-/seed-stage investments accounted for around 60% of VC pharma and biotech deals, up from about 45% in 2009, according to data from PitchBook.

Public opinion and the response to the pandemic

Pharma’s response to the pandemic also created a sea change in public perception. After decades of a lagging reputation in the public eye and consistent public distrust, the speed and manner in which Covid-19 was handled shifted the view of the industry. 60% of Americans have now a more positive view of the industry because of its response to the pandemic.

People are better able to understand what a pharmaceutical company does and can do for society, with companies moving down a path to create real, progressive change.

The global talent pool

Foreign-born talent makes up a significant piece of the talent pool, and the U.S. life sciences industry would simply not be as powerful without it. At the highest level, companies responsible for developing the Covid-19 vaccine are led by trailblazers from outside of the U.S. Moderna’s co-founder and chairman, Pfizer’s CEO, and BioNTech co-founders are all immigrants – and Moderna’s co-founder, Noubar Afeyan, attributes his “immigrant mindset” to his success.

But the impact of global talent runs throughout organizations. According to the myvisajobs.com 2020 H-1B visa report, there were 4,384 Labor Condition Applications for the Pharmaceutical and Medicine Manufacturing Industry in FY 2019, a 12.4% increase over the previous year. Under the Biden administration, changing regulations and openings for STEM talent are likely to push that number even higher.

Increased commitment to workforce equity and diversity

Currently, people of color make up 32% of roles in Life Sciences, and there is an evolving societal status quo when it comes to diversity and equity in the workforce. According to the Biotechnology Innovation Organization report “Measuring Diversity in the Biotech Industry: Building on an Inclusive Workforce,” responding companies reported that 80% of their employees and 73% of their leaders demonstrate a commitment to creating an inclusive environment. What’s more, 46% of respondents say that diversity and inclusion is one of their organization’s stated values or priorities.

Immigrants’ impact on integrated technology

Artificial Intelligence is a lynchpin for current and future life sciences R&D and distribution — and many of the breakthroughs in AI development are driven by foreign-born scientists. MIT researchers highlight that while residents of Europe and North America make up just 15% of the global population, they’ve contributed over 75% of the breakthroughs in AI in the last 30 years. Researchers from Georgetown University said, “Historically, immigrants have helped America lead the world in technological innovation. Foreign-born talent fuels the U.S. AI sector at every level.”

Foreign-born talent is vital in the U.S. talent marketplace, and especially the life sciences industry.

If you are looking to manage or recruit foreign-born talent and have questions about the visa process, we are always here to connect with you.

Subscribe to the WR Immigration Newsletters

Request an Attorney Consultation

Start the RFP Process

Join the Corporate Benchmarking Roundtable

Related Posts:

4 Takeaways from the 2023 Worldwide ERC Global Workforce Symposium

WR Immigration was proud to sponsor the Worldwide ERC 2023 Global Workforce Symposium held in Boston this year. While at this annual meeting of global mobility professionals, we had a chance to meet with old friends and colleagues, as well as create new connections with whom to share insights on how to bring global mobility practices to the next level. If you couldn’t make the conference—or if you did attend but were overwhelmed by the sheer number of panels from which to choose—we’ve compiled a list of the hottest topics from this year’s symposium. Below, we’ve listed the topics that came up again and again in panels, keynotes, and conversations, plus ideas on what these trends might mean for the global mobility industry as we head into 2024. 1. Resistance is Futile: AI is Taking Over There was no escaping AI at this year’s GWS. In addition to the three panels on AI-related topics listed in the official schedule, there were a slew of new vendors in the exhibit hall offering AI-enhanced solutions to global mobility challenges, and discussion of how AI will transform global mobility seemed to be on everyone’s lips. AI was touted as a means of containing […]

Entry to Russia: 14-Day Quarantine or Testing Requirements

Beginning on July 15, 2020, foreign citizens and those crossing the Russian border on a regular flight, and entering Russia with any purpose except work, must present documentation of a negative COVID-19 test in Russian or English: (1) The document should confirm a negative result for laboratory analysis of COVID-19 infection by polymerase chain reaction (PCR). The test for infection should be done not earlier than three calendar days before entering Russia. (2) Or, instead of the PCR test, the traveler can submit a document confirming the existence of antibodies of immunoglobulin G (IgG). If the traveler does not have such a document, he or she must pass the test within three calendar days of entering Russia. In case of a positive result, a person will have to self-isolate with no contact (quarantine) until a negative test is received. Similar requirements apply to Russian citizens. The entry of foreign citizens is still limited, and only special categories of foreign citizens can enter. Issuance of invitation letters and visas has not yet returned to normal. Persons (Russian citizens as well as foreigners) returning to Russia on flights organized by the Russian government must quarantine for 14 calendar days from the date […]